Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 140

1.

A comprehensive understanding of lowly-hydrolyzed polyvinyl alcohol-based ternary solid dispersions with the use of a combined mixture-process design.

Mori Y, Higashi T, Motoyama K, Ishida M, Onodera R, Arima H.

Drug Dev Ind Pharm. 2019 Jul 4:1-33. doi: 10.1080/03639045.2019.1640720. [Epub ahead of print]

PMID:
31271320
2.

In vivo Efficacy and Safety Evaluation of Lactosyl-β-cyclodextrin as a Therapeutic Agent for Hepatomegaly in Niemann-Pick Type C Disease.

Maeda Y, Motoyama K, Nishiyama R, Higashi T, Onodera R, Nakamura H, Takeo T, Nakagata N, Yamada Y, Ishitsuka Y, Kondo Y, Irie T, Era T, Arima H.

Nanomaterials (Basel). 2019 May 25;9(5). pii: E802. doi: 10.3390/nano9050802.

3.

A case of left ventricular pseudoaneurysm presenting with a visible apex beat.

Masuda S, Shibui T, Onodera R, Ashikaga T.

Eur Heart J Case Rep. 2018 Apr 24;2(2):yty052. doi: 10.1093/ehjcr/yty052. eCollection 2018 Jun. No abstract available.

4.

In Vitro and In Vivo Co-delivery of siRNA and Doxorubicin by Folate-PEG-Appended Dendrimer/Glucuronylglucosyl-β-Cyclodextrin Conjugate.

Mohammed AFA, Higashi T, Motoyama K, Ohyama A, Onodera R, Khaled KA, Sarhan HA, Hussein AK, Arima H.

AAPS J. 2019 Apr 16;21(4):54. doi: 10.1208/s12248-019-0327-9.

PMID:
30993472
5.

DAMP-Inducing Adjuvant and PAMP Adjuvants Parallelly Enhance Protective Type-2 and Type-1 Immune Responses to Influenza Split Vaccination.

Hayashi T, Momota M, Kuroda E, Kusakabe T, Kobari S, Makisaka K, Ohno Y, Suzuki Y, Nakagawa F, Lee MSJ, Coban C, Onodera R, Higashi T, Motoyama K, Ishii KJ, Arima H.

Front Immunol. 2018 Nov 20;9:2619. doi: 10.3389/fimmu.2018.02619. eCollection 2018.

6.

Intravenous infusion of mesenchymal stem cells promotes functional recovery in a rat model of chronic cerebral infarction.

Namioka T, Namioka A, Sasaki M, Kataoka-Sasaki Y, Oka S, Nakazaki M, Onodera R, Suzuki J, Sasaki Y, Nagahama H, Kocsis JD, Honmou O.

J Neurosurg. 2018 Oct 1:1-8. doi: 10.3171/2018.5.JNS18140. [Epub ahead of print]

PMID:
30485210
7.

Intravenous infusion of mesenchymal stem cells for protection against brainstem infarction in a persistent basilar artery occlusion model in the adult rat.

Namioka A, Namioka T, Sasaki M, Kataoka-Sasaki Y, Oka S, Nakazaki M, Onodera R, Suzuki J, Sasaki Y, Nagahama H, Kocsis JD, Honmou O.

J Neurosurg. 2018 Oct 1:1-9. doi: 10.3171/2018.4.JNS173121. [Epub ahead of print]

PMID:
30485204
8.

Theoretical and practical evaluation of lowly hydrolyzed polyvinyl alcohol as a potential carrier for hot-melt extrusion.

Mori Y, Motoyama K, Ishida M, Onodera R, Higashi T, Arima H.

Int J Pharm. 2019 Jan 30;555:124-134. doi: 10.1016/j.ijpharm.2018.11.037. Epub 2018 Nov 15.

PMID:
30448311
9.

Innovation process of mHealth: An overview of FDA-approved mobile medical applications.

Onodera R, Sengoku S.

Int J Med Inform. 2018 Oct;118:65-71. doi: 10.1016/j.ijmedinf.2018.07.004. Epub 2018 Aug 3.

PMID:
30153924
10.

Preservation of interhemispheric cortical connections through corpus callosum following intravenous infusion of mesenchymal stem cells in a rat model of cerebral infarction.

Nagahama H, Nakazaki M, Sasaki M, Kataoka-Sasaki Y, Namioka T, Namioka A, Oka S, Onodera R, Suzuki J, Sasaki Y, Kocsis JD, Honmou O.

Brain Res. 2018 Sep 15;1695:37-44. doi: 10.1016/j.brainres.2018.05.033. Epub 2018 May 23.

PMID:
29802840
11.

Effects of cationic liposomes with stearylamine against virus infection.

Tahara K, Kobayashi M, Yoshida S, Onodera R, Inoue N, Takeuchi H.

Int J Pharm. 2018 May 30;543(1-2):311-317. doi: 10.1016/j.ijpharm.2018.04.001. Epub 2018 Apr 3.

PMID:
29625169
12.

Zinc ions have a potential to attenuate both Ni ion uptake and Ni ion-induced inflammation.

Onodera R, Asakawa S, Segawa R, Mizuno N, Ogasawara K, Hiratsuka M, Hirasawa N.

Sci Rep. 2018 Feb 13;8(1):2911. doi: 10.1038/s41598-018-21014-8.

13.

Nickel ions bind to HSP90β and enhance HIF-1α-mediated IL-8 expression.

Asakawa S, Onodera R, Kasai K, Kishimoto Y, Sato T, Segawa R, Mizuno N, Ogasawara K, Moriya T, Hiratsuka M, Hirasawa N.

Toxicology. 2018 Feb 15;395:45-53. doi: 10.1016/j.tox.2018.01.006. Epub 2018 Jan 31.

PMID:
29355601
14.

Gelation Factors of Pectin for Development of a Powder Form of Gel, Dry Jelly, as a Novel Dosage Form.

Kakino Y, Hishikawa Y, Onodera R, Tahara K, Takeuchi H.

Chem Pharm Bull (Tokyo). 2017;65(11):1035-1044. doi: 10.1248/cpb.c17-00447.

15.

Anti-human neutrophil antigen-1a, -1b, and -2 antibodies in neonates and children with immune neutropenias analyzed by extracted granulocyte antigen immunofluorescence assay.

Onodera R, Kurita E, Taniguchi K, Karakawa S, Okada S, Kihara H, Fujii T, Kobayashi M.

Transfusion. 2017 Nov;57(11):2586-2594. doi: 10.1111/trf.14291. Epub 2017 Aug 20.

PMID:
28833244
16.

Polyhydroxyalkanoates (PHA) production from synthetic waste using Pseudomonas pseudoflava: PHA synthase enzyme activity analysis from P. pseudoflava and P. palleronii.

Venkateswar Reddy M, Mawatari Y, Onodera R, Nakamura Y, Yajima Y, Chang YC.

Bioresour Technol. 2017 Jun;234:99-105. doi: 10.1016/j.biortech.2017.03.008. Epub 2017 Mar 4.

PMID:
28319778
17.

Elevated brain derived neurotrophic factor levels in plasma reflect in vivo functional viability of infused mesenchymal stem cells for stroke in rats.

Nakamura H, Sasaki Y, Sasaki M, Kataoka-Sasaki Y, Oka S, Nakazaki M, Namioka T, Namioka A, Onodera R, Suzuki J, Nagahama H, Mikami T, Wanibuchi M, Kocsis JD, Honmou O.

J Neurosurg Sci. 2019 Feb;63(1):42-49. doi: 10.23736/S0390-5616.17.03989-3. Epub 2017 Feb 8.

PMID:
28181779
18.

Intravenous infusion of mesenchymal stem cells inhibits intracranial hemorrhage after recombinant tissue plasminogen activator therapy for transient middle cerebral artery occlusion in rats.

Nakazaki M, Sasaki M, Kataoka-Sasaki Y, Oka S, Namioka T, Namioka A, Onodera R, Suzuki J, Sasaki Y, Nagahama H, Mikami T, Wanibuchi M, Kocsis JD, Honmou O.

J Neurosurg. 2017 Oct;127(4):917-926. doi: 10.3171/2016.8.JNS16240. Epub 2017 Jan 6.

PMID:
28059661
19.

Topical Diclofenac-Loaded Liposomes Ameliorate Laser-Induced Choroidal Neovascularization in Mice and Non-Human Primates.

Shimazawa M, Inoue Y, Masuda T, Onodera R, Tahara K, Shimizu Y, Mibe Y, Tsuruma K, Takeuchi H, Hara H.

Curr Neurovasc Res. 2017;14(1):46-52. doi: 10.2174/1567202614666161104115440.

PMID:
27823554
20.

Synergic Effects of Rehabilitation and Intravenous Infusion of Mesenchymal Stem Cells After Stroke in Rats.

Sasaki Y, Sasaki M, Kataoka-Sasaki Y, Nakazaki M, Nagahama H, Suzuki J, Tateyama D, Oka S, Namioka T, Namioka A, Onodera R, Mikami T, Wanibuchi M, Kakizawa M, Ishiai S, Kocsis JD, Honmou O.

Phys Ther. 2016 Nov;96(11):1791-1798. Epub 2016 May 12.

PMID:
27174259
21.

Control of Drug Diffusion Behavior of Xanthan and Locust Bean Gum Gel by Agar Gel.

Hishikawa Y, Kakino Y, Tsukamoto H, Tahara K, Onodera R, Takeuchi H.

Chem Pharm Bull (Tokyo). 2016;64(10):1450-1457.

22.

In Vitro and In Vivo Characterization of Drug Nanoparticles Prepared Using PureNano™ Continuous Crystallizer to Improve the Bioavailability of Poorly Water Soluble Drugs.

Tahara K, Nishikawa M, Matsui K, Hisazumi K, Onodera R, Tozuka Y, Takeuchi H.

Pharm Res. 2016 Sep;33(9):2259-68. doi: 10.1007/s11095-016-1964-7. Epub 2016 Jun 14.

PMID:
27301372
23.

Characterization of tableting properties measured with a multi-functional compaction instrument for several pharmaceutical excipients and actual tablet formulations.

Osamura T, Takeuchi Y, Onodera R, Kitamura M, Takahashi Y, Tahara K, Takeuchi H.

Int J Pharm. 2016 Aug 20;510(1):195-202. doi: 10.1016/j.ijpharm.2016.05.024. Epub 2016 May 13.

PMID:
27184101
24.

Topical Use of Angiopoietin-like Protein 2 RNAi-loaded Lipid Nanoparticles Suppresses Corneal Neovascularization.

Taketani Y, Usui T, Toyono T, Shima N, Yokoo S, Kimakura M, Yamagami S, Ohno S, Onodera R, Tahara K, Takeuchi H, Kuroda M.

Mol Ther Nucleic Acids. 2016 Mar 8;5:e292. doi: 10.1038/mtna.2016.1.

25.

Pulmonary liposomal formulations encapsulated procaterol hydrochloride by a remote loading method achieve sustained release and extended pharmacological effects.

Tahara K, Tomida H, Ito Y, Tachikawa S, Onodera R, Tanaka H, Tozuka Y, Takeuchi H.

Int J Pharm. 2016 May 30;505(1-2):139-46. doi: 10.1016/j.ijpharm.2016.03.031. Epub 2016 Mar 21.

PMID:
27012982
26.

Interstitial branch formation within the red nucleus by deep cerebellar nuclei-derived commissural axons during target recognition.

Hara S, Kaneyama T, Inamata Y, Onodera R, Shirasaki R.

J Comp Neurol. 2016 Apr 1;524(5):999-1014. doi: 10.1002/cne.23888. Epub 2015 Sep 24.

PMID:
26356789
27.

Evaluation of antitumor effects of folate-conjugated methyl-β-cyclodextrin in melanoma.

Motoyama K, Onodera R, Tanaka N, Kameyama K, Higashi T, Kariya R, Okada S, Arima H.

Biol Pharm Bull. 2015;38(3):374-9. doi: 10.1248/bpb.b14-00531.

28.

Potential use of fucose-appended dendrimer/α-cyclodextrin conjugates as NF-κB decoy carriers for the treatment of lipopolysaccharide-induced fulminant hepatitis in mice.

Akao C, Tanaka T, Onodera R, Ohyama A, Sato N, Motoyama K, Higashi T, Arima H.

J Control Release. 2014 Nov 10;193:35-41. doi: 10.1016/j.jconrel.2014.07.004. Epub 2014 Jul 11.

PMID:
25020038
29.

Involvement of autophagy in antitumor activity of folate-appended methyl-β-cyclodextrin.

Onodera R, Motoyama K, Tanaka N, Ohyama A, Okamatsu A, Higashi T, Kariya R, Okada S, Arima H.

Sci Rep. 2014 Mar 20;4:4417. doi: 10.1038/srep04417.

30.

Inflammation of colon adenoma in the setting of type 1 autoimmune pancreatitis.

Uehara T, Hamano H, Suga T, Kawa S, Yoshizawa A, Kobayashi Y, Murata K, Oki K, Sano K, Onodera R, Ota H.

Pathol Int. 2014 Feb;64(2):67-74. doi: 10.1111/pin.12139.

PMID:
24629174
31.

Potential use of the complex of doxorubicin with folate-conjugated methyl-β-cyclodextrin for tumor-selective cancer chemotherapy.

Motoyama K, Onodera R, Okamatsu A, Higashi T, Kariya R, Okada S, Arima H.

J Drug Target. 2014 Oct 7;22(3):211-219. doi: 10.3109/1061186X.2013.856012. Epub 2013 Nov 13.

PMID:
24219311
32.

Design and evaluation of folate-appended α-, β-, and γ-cyclodextrins having a caproic acid as a tumor selective antitumor drug carrier in vitro and in vivo.

Okamatsu A, Motoyama K, Onodera R, Higashi T, Koshigoe T, Shimada Y, Hattori K, Takeuchi T, Arima H.

Biomacromolecules. 2013 Dec 9;14(12):4420-8. doi: 10.1021/bm401340g. Epub 2013 Nov 21.

PMID:
24175976
33.

Involvement of cholesterol depletion from lipid rafts in apoptosis induced by methyl-β-cyclodextrin.

Onodera R, Motoyama K, Okamatsu A, Higashi T, Kariya R, Okada S, Arima H.

Int J Pharm. 2013 Aug 16;452(1-2):116-23. doi: 10.1016/j.ijpharm.2013.04.071. Epub 2013 May 14.

PMID:
23684659
34.

Folate-appended β-cyclodextrin as a promising tumor targeting carrier for antitumor drugs in vitro and in vivo.

Okamatsu A, Motoyama K, Onodera R, Higashi T, Koshigoe T, Shimada Y, Hattori K, Takeuchi T, Arima H.

Bioconjug Chem. 2013 Apr 17;24(4):724-33. doi: 10.1021/bc400015r. Epub 2013 Mar 15.

PMID:
23458386
35.

Potential use of folate-appended methyl-β-cyclodextrin as an anticancer agent.

Onodera R, Motoyama K, Okamatsu A, Higashi T, Arima H.

Sci Rep. 2013;3:1104. doi: 10.1038/srep01104. Epub 2013 Jan 22.

36.

Bilateral cortical hyperactivity detected by fMRI associates with improved motor function following intravenous infusion of mesenchymal stem cells in a rat stroke model.

Suzuki J, Sasaki M, Harada K, Bando M, Kataoka Y, Onodera R, Mikami T, Wanibuchi M, Mikuni N, Kocsis JD, Honmou O.

Brain Res. 2013 Feb 25;1497:15-22. doi: 10.1016/j.brainres.2012.12.028. Epub 2012 Dec 27.

PMID:
23274536
37.

Mesenchymal stem cells: therapeutic outlook for stroke.

Honmou O, Onodera R, Sasaki M, Waxman SG, Kocsis JD.

Trends Mol Med. 2012 May;18(5):292-7. doi: 10.1016/j.molmed.2012.02.003. Epub 2012 Mar 27. Review.

PMID:
22459358
38.

Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke.

Honmou O, Houkin K, Matsunaga T, Niitsu Y, Ishiai S, Onodera R, Waxman SG, Kocsis JD.

Brain. 2011 Jun;134(Pt 6):1790-807. doi: 10.1093/brain/awr063. Epub 2011 Apr 14.

39.

Topical insulin-like growth factor 1 treatment using gelatin hydrogels for glucocorticoid-resistant sudden sensorineural hearing loss: a prospective clinical trial.

Nakagawa T, Sakamoto T, Hiraumi H, Kikkawa YS, Yamamoto N, Hamaguchi K, Ono K, Yamamoto M, Tabata Y, Teramukai S, Tanaka S, Tada H, Onodera R, Yonezawa A, Inui K, Ito J.

BMC Med. 2010 Nov 25;8:76. doi: 10.1186/1741-7015-8-76.

40.

Cloning, characterization, and expression of xyloglucan endotransglucosylase/hydrolase and expansin genes associated with petal growth and development during carnation flower opening.

Harada T, Torii Y, Morita S, Onodera R, Hara Y, Yokoyama R, Nishitani K, Satoh S.

J Exp Bot. 2011 Jan;62(2):815-23. doi: 10.1093/jxb/erq319. Epub 2010 Oct 19.

41.

Bone marrow mononuclear cells versus G-CSF-mobilized peripheral blood mononuclear cells for treatment of lower limb ASO: pooled analysis for long-term prognosis.

Onodera R, Teramukai S, Tanaka S, Kojima S, Horie T, Matoba S, Murohara T, Matsubara H, Fukushima M; BMMNC Follow-Up Study Investigators; M-PBMNC Follow-Up Study Investigators.

Bone Marrow Transplant. 2011 Feb;46(2):278-84. doi: 10.1038/bmt.2010.110. Epub 2010 May 17.

PMID:
20479708
42.

Successful bone marrow transplantation in chronic granulomatous disease.

Miki M, Ono A, Awaya A, Miyagawa S, Onodera R, Kurita E, Hiraoka A, Hidaka F, Mizukami T, Nunoi H, Kobayashi M.

Pediatr Int. 2009 Dec;51(6):838-41. doi: 10.1111/j.1442-200X.2009.02931.x. No abstract available.

PMID:
20158628
43.

Long-term clinical outcomes for patients with lower limb ischemia implanted with G-CSF-mobilized autologous peripheral blood mononuclear cells.

Horie T, Onodera R, Akamastu M, Ichikawa Y, Hoshino J, Kaneko E, Iwashita C, Ishida A, Tsukamoto T, Teramukai S, Fukushima M, Kawamura A; Japan Study Group of Peripheral Vascular Regeneration Cell Therapy (JPRCT).

Atherosclerosis. 2010 Feb;208(2):461-6. doi: 10.1016/j.atherosclerosis.2009.07.050. Epub 2009 Aug 3.

PMID:
19720375
44.

Intramuscular transplantation of G-CSF-mobilized CD34(+) cells in patients with critical limb ischemia: a phase I/IIa, multicenter, single-blinded, dose-escalation clinical trial.

Kawamoto A, Katayama M, Handa N, Kinoshita M, Takano H, Horii M, Sadamoto K, Yokoyama A, Yamanaka T, Onodera R, Kuroda A, Baba R, Kaneko Y, Tsukie T, Kurimoto Y, Okada Y, Kihara Y, Morioka S, Fukushima M, Asahara T.

Stem Cells. 2009 Nov;27(11):2857-64. doi: 10.1002/stem.207.

45.

Involvement of PI3K-Akt-Bad pathway in apoptosis induced by 2,6-di-O-methyl-beta-cyclodextrin, not 2,6-di-O-methyl-alpha-cyclodextrin, through cholesterol depletion from lipid rafts on plasma membranes in cells.

Motoyama K, Kameyama K, Onodera R, Araki N, Hirayama F, Uekama K, Arima H.

Eur J Pharm Sci. 2009 Oct 8;38(3):249-61. doi: 10.1016/j.ejps.2009.07.010. Epub 2009 Aug 5.

PMID:
19664706
46.

Dizygotic twins with neonatal alloimmune neutropenia associated with maternal anti-human neutrophil antigen-1B antibody.

Higashigawa M, Nishimori H, Komada Y, Onodera R, Hiraoka A, Kobayashi M.

Pediatr Int. 2009 Apr;51(2):297-9. doi: 10.1111/j.1442-200X.2009.02819.x. No abstract available.

PMID:
19379263
47.

Involvement of lipid rafts of rabbit red blood cells in morphological changes induced by methylated beta-cyclodextrins.

Motoyama K, Toyodome H, Onodera R, Irie T, Hirayama F, Uekama K, Arima H.

Biol Pharm Bull. 2009 Apr;32(4):700-5.

48.

[A case of pericardial malignant mesothelioma accompanied by primary lung adenocarcinoma].

Nojiri S, Yumino Y, Sato K, Onodera R, Nakayama K, Kuwano K.

Nihon Kokyuki Gakkai Zasshi. 2009 Feb;47(2):104-9. Japanese.

PMID:
19260532
49.

Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia.

Matoba S, Tatsumi T, Murohara T, Imaizumi T, Katsuda Y, Ito M, Saito Y, Uemura S, Suzuki H, Fukumoto S, Yamamoto Y, Onodera R, Teramukai S, Fukushima M, Matsubara H; TACT Follow-up Study Investigators.

Am Heart J. 2008 Nov;156(5):1010-8. doi: 10.1016/j.ahj.2008.06.025. Epub 2008 Sep 19.

PMID:
19061721
50.

Two-wavelength interferometry that uses a fourier-transform method.

Onodera R, Ishii Y.

Appl Opt. 1998 Dec 1;37(34):7988-94.

PMID:
18301689

Supplemental Content

Loading ...
Support Center